Free Access
| Issue |
Med Sci (Paris)
Volume 28, Number 4, Avril 2012
|
|
|---|---|---|
| Page(s) | 358 - 360 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/2012284008 | |
| Published online | 25 April 2012 | |
- UNAIDS 2011, World AIDS Day Report. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDS-day_report_2011_en.pdf. [Google Scholar]
- Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007 ; 131 : 1059–1071. [CrossRef] [PubMed] [Google Scholar]
- Roan NR, Munch J, Arhel N, et al. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol 2009 ; 83 : 73–80. [CrossRef] [PubMed] [Google Scholar]
- Roan NR, Sowinski S, Munch J, et al. Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem 2010 ; 285 : 1861–1869. [CrossRef] [PubMed] [Google Scholar]
- Roan NR, Muller JA, Liu H, et al. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 2011 ; 10 : 541–550. [CrossRef] [PubMed] [Google Scholar]
- Olsen JS, Brown C, Capule CC, et al. Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J Biol Chem 2010 ; 285 : 35488–35496. [CrossRef] [PubMed] [Google Scholar]
- Bouvet JP, Gresenguet G, Belec L. Vaginal pH neutralization by semen as a cofactor of HIV transmission. Clin Microbiol Infect 1997 ; 3 : 19–23. [CrossRef] [PubMed] [Google Scholar]
- Tevi-Benissan C, Belec L, Levy M, et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 1997 ; 4 : 367–374. [PubMed] [Google Scholar]
- Gupta K, Klasse PJ. How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 2006 ; 3 : e79. [CrossRef] [PubMed] [Google Scholar]
- McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010 ; 376 : 1329–1337. [CrossRef] [PubMed] [Google Scholar]
- Yoshida K, Yamasaki T, Yoshiike M, et al. Quantification of seminal plasma motility inhibitor/semenogelin in human seminal plasma. J Androl 2003 ; 24 : 878–884. [PubMed] [Google Scholar]
- Ronnberg L, Vihko P, Sajanti E, Vihko R. Clomiphene citrate administration to normogonadotropic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int J Androl 1981 ; 4 : 372–378. [CrossRef] [PubMed] [Google Scholar]
- Kim KA, Yolamanova M, Zirafi O, et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 2010 ; 7 : 55. [CrossRef] [PubMed] [Google Scholar]
- Linke RP, Joswig R, Murphy CL, et al. Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med 2005 ; 145 : 187–193. [CrossRef] [PubMed] [Google Scholar]
- Doncel GF. Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides. Hum Reprod Update 2006 ; 12 : 103–117. [CrossRef] [PubMed] [Google Scholar]
- Sievers SA, Karanicolas J, Chang HW, et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011 ; 475 : 96–100. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.